Showing posts with label cancer treatment induced bone loss. Show all posts
Showing posts with label cancer treatment induced bone loss. Show all posts
Friday, July 23, 2010
Tuesday, June 15, 2010
Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer -- Konstantinopoulos et al., 10.1200/JCO.2009.27.5719 -- Journal of Clinical Oncology
add your opinions
BRCAness
,
cancer treatment induced bone loss
,
gene expression
,
response
Monday, April 12, 2010
Emerging drugs for the management of cancer treatment induced bone loss; Expert Opinion on Emerging Drugs
Take home message: The very high rate of bone loss and the high incidence of fractures indicate that cancer patients at risk of CTIBL (cancer treatment induced bone loss) need to be carefully monitored and stratified for fracture risk. Although there is a strong evidence of efficacy in prevention of bone loss and reduction of fracture risk for many drugs approved for postmenopausal osteoporosis (PMO) and male osteoporosis, for CTIBL there are actually no drugs approved for this indication.
add your opinions
bone loss
,
cancer treatment induced bone loss
,
fracture
,
osteoporois
Subscribe to:
Posts
(
Atom
)